UT MD Anderson CCOP Research Base

描述（由申请人提供）：自授予其第一个NCI以来 1987年，德克萨斯大学医学博士安德森癌症中心社区 临床肿瘤学计划（MDACCOP）研究基地管理了150个临床 试验涉及5，000多名患者，其中2，688名患者进入 进行化学预防试验MDACCOP研究基地将继续 开展并支持一系列癌症控制的临床研究， 预防和治疗，可以有效地实施和进行， 社区环境。该研究基地及其附属的CCOP网站有 充分的支持和机构资源，包括临床研究 基础设施，MDACC，世界？最大和排名最高的 综合癌症中心建议的具体目标如下： 1.为附属CCOP和MBCCOP提供MDACC临床试验的访问权限。 2.从学术中心转移信息、技术和标准 对社区的贡献 3.加强预防和控制试验的发展，包括 行为干预，化学预防试验，症状控制， 识别癌症或癌症复发风险增加的个体 他们的癌症，以及社区健康结果研究的发展 设置. 4.将妇科肿瘤小组的CCOP纳入MDACCOP经常预算; 使目前的MDACCOPs能够访问GOG研究，并与 另一个RB（作为第五附属公司）。 5.开发新的方法来回答癌症控制问题， 多机构设置，如远程症状评估，并建立 为在全国范围内开展这些研究建立的教育支助系统， 社区 6.提供增加征聘少数群体成员的战略 用于临床和癌症控制试验的群体和妇女。 7.维护一个将MDACC与 附属CCOP和MBCCOP。该系统确保了准确的收集和 为研究试验传输信息，并提供设施， 加强持续的质量保证、数据监测和现场审计。 8.与NCI社区肿瘤学和预防试验研究小组合作 为了确保RB的研究计划与目标一致， 国家方案。

DESCRIPTION (provided by applicant): Since the awarding of its first NCI Grant in 1987, the University of Texas M.D. Anderson Cancer Center Community Clinical Oncology Program (MDACCOP) Research Base has managed 150 clinical trials involving more than 5,000 patients, including 2,688 patients entered onto chemoprevention trials. The MDACCOP Research Base will continue to generate and support a spectrum of clinical studies of cancer control, prevention and therapy that can be implemented and conducted efficiently in a community environment. The Research Base and its affiliated CCOP sites have the full support and institutional resources, including the clinical research infrastructure, of the MDACC, the world?s largest and highest ranked comprehensive cancer center. The following specific aims are proposed: 1. Provide affiliate CCOPs and MBCCOPs access to MDACC clinical trials. 2. Transfer information, technology, and standards from the academic centers to the community. 3. Enhance the development of prevention and control trials that include behavioral interventions, chemoprevention trials, symptom control, the identification of individuals at increased risk for cancer or recurrence of their cancer, and the development of health outcomes research in the community setting. 4. Integrate the Gynecology Oncology Group (GOG) CCOPs into the MDACCOP RB; enable the current MDACCOPs to access the GOG studies and affiliate with another RB (as a 5th affiliate). 5. Develop new methodologies for answering cancer control questions in a multi-institutional setting, such as remote symptom assessment, and establish the educational support systems for initiation of these studies in the community. 6. Provide strategies to increase the recruitment of members of minority groups and women for clinical and cancer control trials. 7. Maintain a comprehensive data management system that links MDACC to the affiliate CCOPs and MBCCOPs. This system ensures the accurate collection and transmission of information for research trials and provides a facility to enhance ongoing quality assurance, data monitoring, and on-site audits. 8. Work with the NCI Community Oncology and Prevention Trials Research Group to ensure the research programs of the RB are congruent with the goals of the national program.